Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

In this study, the KPAI and KP-IGA scoring systems for assessing keratosis pilaris showed excellent interrater and intrarater reliability, offering standardized measures for clinical and research use.

This article presents the SH-1 molecule as a novel AR antagonist for androgenetic alopecia treatment, highlighting its tissue-specific action and potential for commercialization, but provides no new clinical results.

This study found that a cholesterol-conjugated, cell-penetrating asiRNA targeting the androgen receptor effectively reduced hair loss and promoted hair growth in mouse models of androgenetic alopecia, suggesting potential as a novel treatment.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

This study found a recurrent nonsense mutation in the HR gene linked to atrichia with papular lesions in two Kashmiri families, suggesting whole exome sequencing as an efficient method for diagnosis and genetic counseling.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

This chapter discusses procedural therapies like platelet-rich plasma and low-level light therapy for androgenetic alopecia, but reports no new clinical findings.

This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

In this study, treatment of unwanted hair with 755 nm alexandrite laser in 14 patients showed a decrease in excess hair at the armpit and thigh areas, with a 75% accuracy rate in hair density estimation using Monte Carlo modeling.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

This study demonstrated that an AR-EGFP transgene can restore AR function and fertility in Sertoli cell-specific AR knockout mice, highlighting its potential use in understanding androgen receptor functions.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This study describes a multifunctional hydrogel system designed to treat androgenetic alopecia by integrating nanozymes for reactive oxygen species clearance and melanin nano photothermal agents to enhance hair follicle health, suggesting potential for multi-target precision therapy and improved hair growth.

This case study reports that a 26-year-old woman with epidermolysis bullosa prurogompsa also presented with unique findings of co-existing muscular dystrophy and immune-based myasthenia gravis, with significant improvement following steroid treatment.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

In this study, AgK114 was found to be transiently induced in hamster epidermal keratinocytes following skin damage, suggesting its role in the recovery process after injury.

In this preclinical study, PA-011 derived from Periplaneta americana showed significant hair regrowth effects in androgenetic alopecia mouse models by inhibiting inflammation and oxidative stress, activating hair follicle stem cell proliferation, and normalizing skin microbiota, suggesting promise as an AGA treatment.

The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.

This study found that shorter GGN repeat lengths (≤23) in the androgen receptor gene are associated with androgenetic alopecia among Chinese males, whereas two specific SNPs studied were not present in this population.

In this report, a 58-year-old woman with ocular myasthenia gravis experienced complete resolution of symptoms and hair regrowth after six months of treatment with the JAK inhibitor baricitinib, highlighting a potential new therapeutic approach for this condition.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.